Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein?based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

Persistent Genital Human Papillomavirus Infection as a Risk Factor for Persistent Cervical Dysplasia

Gloria Y. F. Ho, Robert D. Burk, S. Klein et al. · JNCI Journal of the National Cancer Institute · 1995 · 818 citations

Medicine, Obstetrics, Pathology +17

Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study

Susanne K. Kjær, Adriaan J. C. van den Brule, Gerson Paull et al. · BMJ · 2002 · 423 citations · Full text

Medicine, Oncology, Pathology +17

A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

Laila I. Muderspach, Sharon P. Wilczynski, Lynda D. Roman et al. · PubMed · 2000 · 311 citations

Medicine, Immunology, Oncology +17

Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.

Barbara Klencke, Mark Matijevic, Robert G. Urban et al. · PubMed · 2002 · 230 citations

Medicine, Immunology, Oncology +17

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I–II trial

Willemien J. van Driel, Maaike E. Ressing, Gemma G. Kenter et al. · European Journal of Cancer · 1999 · 230 citations

Medicine, Immunology, Oncology +15